NCT04588298View on ClinicalTrials.gov

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

June 19, 2023

Study Completion Date

June 19, 2023

Conditions
HER2-negative Breast Cancer
Interventions
DRUG

AZD9833

AZD9833 tablets will be administered orally.

Trial Locations (12)

6000

Research Site, Batumi

20230

Research Site, Aguascalientes

'0112

Research Site, Tbilisi

'0186

Research Site, Tbilisi

0159

Research Site, Tbilisi

0179

Research Site, Tbilisi

'14080

Research Site, Mexico City

DE22 3NE

Research Site, Derby

LE1 5WW

Research Site, Leicester

L7 8XP

Research Site, Liverpool

W12 0HS

Research Site, London

M23 9LT

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY